Respondent characteristics | IVIg cohort (n = 54) (A) | SCIg cohort (n = 242) (B) | SCIg naïve subgroup (n = 65) (C) | SCIg switch subgroup (n = 151) (D) | p values | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | Summary | n | Summary | n | Summary | n | Summary | n | A vs. B | A vs. C | A vs. D | |
Age (years), median [IQR] | 60 [37, 67] | 54 | 59 [48, 67] | 242 | 64 [52, 68] | 65 | 57 [45, 64] | 151 | 0.43 | 0.13 | 0.94 | |
Age at diagnosis (years), median [IQR] | 38 [18, 60] | 54 | 45 [27, 60] | 239 | 54 [40, 64] | 63 | 40 [23, 54] | 150 | 0.23 | 0.003 | 0.79 | |
Gender, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
 Female | 24 (44.4%) | 54 | 151 (63.0%) | 240 | 35 (54.7%) | 64 | 94 (62.7%) | 150 | 0.01 | 0.27 | 0.02 | |
 Male | 30 (55.6%) |  | 89 (37.1%) |  | 29 (45.3%) |  | 56 (37.3%) |  | ||||
Weight (kg) | 74.2 ± 15.1 | 47 | 75.8 ± 17.4 | 216 | 80.5 ± 15.3 | 53 | 73.8 ± 16.3 | 138 | 0.56 | 0.05 | 0.89 | |
Underlying condition, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | |||
 CVID | 21 (51.2%) | 41 | 85 (45.0%) | 189 | 20 (41.7%) | 48 | 56 (45.5%) | 123 | 0.35 | 0.32 | 0.23 | |
 IgG Sub | 9 (22.0%) |  | 48 (25.4%) |  | 10 (20.8%) |  | 35 (28.5%) |  |  |  |  | |
 DGS | 2 (4.9%) |  | 8 (4.2%) |  | 4 (8.3%) |  | 3 (2.4) |  |  |  |  | |
 SID | 1 (2.4%) |  | 22 (11.6%) |  | 7 (14.6%) |  | 14 (11.4%) |  |  |  |  | |
 Other* | 8 (19.5%) |  | 26 (13.8%) |  | 7 (14.6%) |  | 15 (12.2%) |  |  |  |  | |
Years since diagnosis, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||
  < 2 years | 3 (5.6%) | 54 | 16 (6.7%) | 239 | 10 (15.9%) | 63 | 5 (3.3%) | 150 | 0.24 |  < 0.001 | 0.74 | |
 2–9 years | 20 (37.0%) |  | 116 (48.5%) |  | 41 (65.1%) |  | 60 (40.0%) |  |  |  |  | |
  ≥ 10 years | 31 (57.4%) |  | 107 (44.8%) |  | 12 (19.1%) |  | 85 (56.7%) |  |  |  |  | |
Time on IgG, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | |||
  < 1 year | 1 (1.9%) | 54 | 11 (4.6%) | 242 | 7 (10.8%) | 65 | 3 (2.0%) | 151 | 0.6 |  < 0.001 | 0.82 | |
 1–2 years | 5 (9.3%) |  | 35 (14.5%) |  | 10 (15.4%) |  | 21 (13.9%) |  |  |  |  | |
 2–3 years | 7 (13.0%) |  | 31 (12.8%) |  | 13 (20.0%) |  | 13 (8.6%) |  |  |  |  | |
 4–6 years | 11 (20.4%) |  | 55 (22.7%) |  | 24 (36.9%) |  | 24 (15.9%) |  |  |  |  | |
  ≥ 6 years | 30 (55.6%) |  | 110 (45.5%) |  | 11 (16.9%) |  | 90 (59.6%) |  |  |  |  | |
Current treatment experience, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | ||||
  < 2 years | 4 (8.5%) | 47 | 35 (14.7%) | 238 | 12 (18.5%) | 65 | 20 (13.5%) | 148 | 0.02 |  < 0.001 | 0.23 | |
 2–9 years | 23 (48.9%) |  | 148 (62.2%) |  | 46 (70.8%) |  | 84 (56.8%) |  |  |  |  | |
 ≥ 10 years | 20 (42.6%) |  | 55 (23.1%) |  | 7 (10.8%) |  | 44 (29.7%) |  |  |  |  | |
Antibiotics before IgG, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | Â | |||
 No | 29 (70.7%) | 41 | 157 (73.7%) | 213 | 48 (81.4%) | 59 | 94 (71.2%) | 132 | 0.69 | 0.21 | 0.95 | |
 Yes | 12 (29.3%) |  | 56 (26.3%) |  | 11 (18.6%) |  | 38 (28.8%) |  |  |  |  | |
Antibiotics since starting IgG, n (%) | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 No | 9 (21.4%) | 42 | 91 (39.6%) | 230 | 29 (46.0%) | 63 | 53 (37.1%) | 143 | 0.03 | 0.01 | 0.06 | |
 Yes | 33 (78.6%) |  | 139 (60.4%) |  | 34 (54.0%) |  | 90 (62.9%) |  |  |  |  | |
Missed work/school due to treatment regimen, n (%) | Â | Â | Â | Â | Â | Â | Â | |||||
 No | 36 (66.7%) | 54 | 221 (91.7%) | 2 | 63 (96.7%) | 65 | 134 (89.3%) | 150 |  < 0.001 |  < 0.001 |  < 0.001 | |
 Yes | 18 (33.3%) |  | 20 (8.3%) |  | 2 (3.1%) |  | 16 (10.7%) |  |  |  |  |